{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:56:43Z","timestamp":1791284203799,"version":"4.1.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Pityriasis rosea (PR) is an acute exanthematous disease with an uncertain physiopathology, increasingly recognized as potentially drug induced. This study aims to investigate medication triggers associated with PR by analyzing cases reported in the FDA Adverse Event Reporting System (FAERS) database. A retrospective review of 343 PR cases reported in the FAERS database from January 1, 1998, to March 31, 2024, was conducted. Reporting odds ratios (ROR) were calculated to assess associations between PR and specific drug classes, including tumor necrosis factor (TNF) inhibitors and angiotensin-converting enzyme (ACE) inhibitors. Logistic regression analysis evaluated the influence of factors such as sex, age group, and seriousness of outcomes on the occurrence of PR. Females represented 56.3% of cases and the 18\u201364 age group comprised 55.4% of cases. TNF inhibitors were significantly associated with PR (ROR\u2009=\u20094.1881 [3.1970\u20135.4865], <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001), particularly infliximab (ROR\u2009=\u20096.5284 [3.9523\u201310.7837], <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001), etanercept (ROR\u2009=\u20093.4921 [2.2873\u20135.3315], <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001), and adalimumab (ROR\u2009=\u20093.086 [2.0213\u20134.7115], <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001). ACE inhibitors were also associated with PR (ROR\u2009=\u20099.9808 [6.0423\u201316.4864], <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001), with higher odds in older patients (OR 14.08 [4.2\u201347.2], <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001) and those reporting serious outcomes (OR 9.53 [1.24\u201372.99], <jats:italic>P<\/jats:italic>\u2009=\u20090.03). Based on the FAERS, there has been a consistent rise in PR cases, with TNF inhibitors and ACE inhibitors being associated medication classes tied to PR. Given the limited literature on drug-related triggers and patient demographics, we aimed to highlight the characteristics of PR cases that could enhance awareness and inform better clinical outcomes for affected patients.<\/jats:p>","DOI":"10.1007\/s00403-024-03763-x","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T12:02:14Z","timestamp":1736769734000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A retrospective analysis of medications associated with pityriasis rosea reported in the FDA adverse events reporting system"],"prefix":"10.1007","volume":"317","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9577-5092","authenticated-orcid":false,"given":"Kayla D.","family":"Mashoudy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joselyn","family":"Ye-Tay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyvan","family":"Nouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,13]]},"reference":[{"key":"3763_CR1","volume-title":"Pityriasis Rosea. StatPearls. Treasure Island (FL) ineligible companies","author":"G Litchman","year":"2024","unstructured":"Litchman G, Nair PA, Syed HA, Le JK (2024) Disclosure: Pragya Nair declares no relevant financial relationships with ineligible companies. Disclosure: Hasnain Syed declares no relevant financial relationships with ineligible companies. Pityriasis Rosea. StatPearls. Treasure Island (FL) ineligible companies. Jacqueline Le declares no relevant financial relationships with ineligible companies., Disclosure"},{"key":"3763_CR2","first-page":"87","volume":"69","author":"DL Stulberg","year":"2004","unstructured":"Stulberg DL, Wolfrey J (2004) Pityriasis Rosea. Am Fam Physician 69:87\u201391","journal-title":"Am Fam Physician"},{"key":"3763_CR3","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/j.1525-1470.2003.20603.x","volume":"20","author":"AA Chuh","year":"2003","unstructured":"Chuh AA (2003) Quality of life in children with pityriasis rosea: a prospective case control study. Pediatr Dermatol 20:474\u2013478. https:\/\/doi.org\/10.1111\/j.1525-1470.2003.20603.x","journal-title":"Pediatr Dermatol"},{"key":"3763_CR4","first-page":"367","volume":"20","author":"Y Kaymak","year":"2008","unstructured":"Kaymak Y, Taner E (2008) Anxiety and depression in patients with pityriasis rosea compared to patients with tinea versicolor. Dermatol Nurs 20:367\u2013370","journal-title":"Dermatol Nurs"},{"key":"3763_CR5","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1159\/000445375","volume":"232","author":"F Drago","year":"2016","unstructured":"Drago F, Ciccarese G, Rebora A, Broccolo F, Parodi A (2016) Pityriasis Rosea: a comprehensive classification. Dermatology 232:431\u2013437. https:\/\/doi.org\/10.1159\/000445375","journal-title":"Dermatology"},{"key":"3763_CR6","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1017\/s0950268804002304","volume":"132","author":"A Chuh","year":"2004","unstructured":"Chuh A, Chan H, Zawar V (2004) Pityriasis rosea\u2013evidence for and against an infectious aetiology. Epidemiol Infect 132:381\u2013390. https:\/\/doi.org\/10.1017\/s0950268804002304","journal-title":"Epidemiol Infect"},{"key":"3763_CR7","doi-asserted-by":"publisher","first-page":"664","DOI":"10.2340\/00015555-3169","volume":"99","author":"M Yuksel","year":"2019","unstructured":"Yuksel M (2019) Pityriasis Rosea Recurrence is much higher than previously known: a prospective study. Acta Derm Venereol 99:664\u2013667. https:\/\/doi.org\/10.2340\/00015555-3169","journal-title":"Acta Derm Venereol"},{"key":"3763_CR8","doi-asserted-by":"publisher","first-page":"311","DOI":"10.4103\/0378-6323.16779","volume":"71","author":"A Chuh","year":"2005","unstructured":"Chuh A, Lee A, Zawar V, Sciallis G, Kempf W (2005) Pityriasis rosea\u2013an update. Indian J Dermatol Venereol Leprol 71:311\u2013315. https:\/\/doi.org\/10.4103\/0378-6323.16779","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"3763_CR9","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1002\/jmv.27672","volume":"94","author":"G Ciccarese","year":"2022","unstructured":"Ciccarese G, Drago F, Marinaro E, Parodi A (2022) Pityriasis Rosea during COVID-19: Pathogenesis, diagnosis, and treatment. J Med Virol 94:2915\u20132916. https:\/\/doi.org\/10.1002\/jmv.27672","journal-title":"J Med Virol"},{"key":"3763_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5070\/D380D8301D","volume":"12","author":"L Atzori","year":"2006","unstructured":"Atzori L, Pinna AL, Ferreli C, Aste N (2006) Pityriasis Rosea-like adverse reaction: review of the literature and experience of an Italian drug-surveillance center. Dermatol Online J 12:1","journal-title":"Dermatol Online J"},{"key":"3763_CR11","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1111\/bcp.13560","volume":"84","author":"MM Alame","year":"2018","unstructured":"Alame MM, Chamsy DJ, Zaraket H (2018) Pityriasis Rosea-like eruption associated with ondansetron use in pregnancy. Br J Clin Pharmacol 84:1077\u20131080. https:\/\/doi.org\/10.1111\/bcp.13560","journal-title":"Br J Clin Pharmacol"},{"key":"3763_CR12","volume-title":"Herald Patch. StatPearls. Treasure Island (FL) companies. Disclosure: Madiha Huq declares no relevant financial relationships with ineligible companies. Disclosure: Haitham Saleh declares no relevant financial relationships with ineligible companies","author":"JT Gay","year":"2024","unstructured":"Gay JT, Huq ME, Saleh HM, Gross GP (2024) Herald Patch. StatPearls. Treasure Island (FL) companies. Disclosure: Madiha Huq declares no relevant financial relationships with ineligible companies. Disclosure: Haitham Saleh declares no relevant financial relationships with ineligible companies. Gary Gross declares no relevant financial relationships with ineligible companies., Disclosure"},{"key":"3763_CR13","doi-asserted-by":"publisher","first-page":"9503","DOI":"10.4081\/dr.2022.9503","volume":"15","author":"S Veraldi","year":"2023","unstructured":"Veraldi S, Boneschi V, Cusini M, Maronese CA (2023) Pityriasis Rosea and pityriasis rosea-like eruption after anti-SARS-CoV-2 vaccination: a report of five cases and review of the literature. Dermatol Rep 15:9503. https:\/\/doi.org\/10.4081\/dr.2022.9503","journal-title":"Dermatol Rep"},{"key":"3763_CR14","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1111\/jocd.15755","volume":"22","author":"G Ciccarese","year":"2023","unstructured":"Ciccarese G, Mastrolonardo M, Serviddio G, Drago F (2023) Maculopapular eruptions following COVID-19 vaccination: Pityriasis Rosea or pityriasis rosea-like eruptions? J Cosmet Dermatol 22:2380\u20132381. https:\/\/doi.org\/10.1111\/jocd.15755","journal-title":"J Cosmet Dermatol"},{"key":"3763_CR15","doi-asserted-by":"publisher","first-page":"e804","DOI":"10.1002\/iid3.804","volume":"11","author":"I Khan","year":"2023","unstructured":"Khan I, Elsanousi AA, Shareef AM, Tebha SS, Arif A, Gul S (2023) Manifestation of pityriasis rosea and pityriasis rosea-like eruptions after Covid-19 vaccine: a systematic review. Immun Inflamm Dis 11:e804. https:\/\/doi.org\/10.1002\/iid3.804","journal-title":"Immun Inflamm Dis"},{"key":"3763_CR16","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaad.2021.03.092","volume":"85","author":"DE McMahon","year":"2021","unstructured":"McMahon DE, Amerson E, Rosenbach M, Lipoff JB, Moustafa D, Tyagi A et al (2021) Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol 85:46\u201355. https:\/\/doi.org\/10.1016\/j.jaad.2021.03.092","journal-title":"J Am Acad Dermatol"},{"key":"3763_CR17","doi-asserted-by":"publisher","first-page":"e25352","DOI":"10.1097\/MD.0000000000025352","volume":"100","author":"V Birlutiu","year":"2021","unstructured":"Birlutiu V, Birlutiu RM, Iancu GM (2021) Pityriasis Rosea Gibert triggered by SARS-CoV-2 infection: a case report. Med (Baltim) 100:e25352. https:\/\/doi.org\/10.1097\/MD.0000000000025352","journal-title":"Med (Baltim)"},{"key":"3763_CR18","doi-asserted-by":"publisher","first-page":"315","DOI":"10.4103\/ijd.IJD_51_19","volume":"67","author":"IG Isik","year":"2022","unstructured":"Isik IG, Cakmak SK, Ozhamam E (2022) A rare case of Pityriasis Rosea-like Lichenoid Drug Eruption due to Imatinib Treatment. Indian J Dermatol 67:315. https:\/\/doi.org\/10.4103\/ijd.IJD_51_19","journal-title":"Indian J Dermatol"},{"key":"3763_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2020.01.010","author":"S Valenzuela-Ubina","year":"2021","unstructured":"Valenzuela-Ubina S, Villegas-Romero I, Jimenez-Gallo D, Linares-Barrios M (2021) Pityriasis Rosea-like Eruption Induced by Imatinib in a patient with a gastrointestinal stromal tumor. Actas Dermosifiliogr (Engl Ed). https:\/\/doi.org\/10.1016\/j.ad.2020.01.010","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"3763_CR20","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1111\/j.1468-3083.2007.02197.x","volume":"21","author":"SN Rajpara","year":"2007","unstructured":"Rajpara SN, Ormerod AD, Gallaway L (2007) Adalimumab-induced pityriasis rosea. J Eur Acad Dermatol Venereol 21:1294\u20131296. https:\/\/doi.org\/10.1111\/j.1468-3083.2007.02197.x","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3763_CR21","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/1346-8138.12445","volume":"41","author":"T Ohtsuka","year":"2014","unstructured":"Ohtsuka T (2014) Pityriasis Rosea-like arranged eruption after infliximab therapy in a patient with psoriasis vulgaris. J Dermatol 41:354\u2013355. https:\/\/doi.org\/10.1111\/1346-8138.12445","journal-title":"J Dermatol"},{"key":"3763_CR22","first-page":"383","volume":"13","author":"C Guarneri","year":"2009","unstructured":"Guarneri C, Polimeni G, Nunnari G (2009) Pityriasis Rosea during etanercept therapy. Eur Rev Med Pharmacol Sci 13:383\u2013387","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"3763_CR23","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJ (2009) Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf 18:427\u2013436. https:\/\/doi.org\/10.1002\/pds.1742","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3763_CR24","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","volume":"72","author":"JL Montastruc","year":"2011","unstructured":"Montastruc JL, Sommet A, Bagheri H, Lapeyre-Mestre M (2011) Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol 72:905\u2013908. https:\/\/doi.org\/10.1111\/j.1365-2125.2011.04037.x","journal-title":"Br J Clin Pharmacol"},{"key":"3763_CR25","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1023\/a:1007412330146","volume":"14","author":"M Harman","year":"1998","unstructured":"Harman M, Aytekin S, Akdeniz S, Inaloz HS (1998) An epidemiological study of pityriasis rosea in the Eastern Anatolia. Eur J Epidemiol 14:495\u2013497. https:\/\/doi.org\/10.1023\/a:1007412330146","journal-title":"Eur J Epidemiol"},{"key":"3763_CR26","doi-asserted-by":"publisher","first-page":"e21194","DOI":"10.7759\/cureus.21194","volume":"14","author":"J Gandhi","year":"2022","unstructured":"Gandhi J, Agrawal S, Gupta S, Verma K, Mohite A (2022) Pattern of Papulosquamous disorders in children: a clinico-epidemiological study. Cureus 14:e21194. https:\/\/doi.org\/10.7759\/cureus.21194","journal-title":"Cureus"},{"key":"3763_CR27","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/jdv.12701","volume":"29","author":"F Guarneri","year":"2015","unstructured":"Guarneri F, Cannavo SP, Minciullo PL, Gangemi S (2015) Pityriasis Rosea of Gibert: immunological aspects. J Eur Acad Dermatol Venereol 29:21\u201325. https:\/\/doi.org\/10.1111\/jdv.12701","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3763_CR28","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1001\/archderm.121.6.761","volume":"121","author":"S Aiba","year":"1985","unstructured":"Aiba S, Tagami H (1985) Immunohistologic studies in pityriasis rosea. Evidence for cellular immune reaction in the lesional epidermis. Arch Dermatol 121:761\u2013765. https:\/\/doi.org\/10.1001\/archderm.121.6.761","journal-title":"Arch Dermatol"},{"key":"3763_CR29","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/BF00429978","volume":"280","author":"H Sugiura","year":"1988","unstructured":"Sugiura H, Miyauchi H, Uehara M (1988) Evolutionary changes of immunohistological characteristics of secondary lesions in pityriasis rosea. Arch Dermatol Res 280:405\u2013410. https:\/\/doi.org\/10.1007\/BF00429978","journal-title":"Arch Dermatol Res"},{"key":"3763_CR30","first-page":"209","volume":"68","author":"BS Baker","year":"1988","unstructured":"Baker BS, Lambert S, Powles AV, Valdimarsson H, Fry L (1988) Epidermal DR\u2009+\u2009T6- dendritic cells in inflammatory skin diseases. Acta Derm Venereol 68:209\u2013217","journal-title":"Acta Derm Venereol"},{"key":"3763_CR31","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/j.1365-2230.2009.03469.x","volume":"35","author":"CY Neoh","year":"2010","unstructured":"Neoh CY, Tan AW, Mohamed K, Sun YJ, Tan SH (2010) Characterization of the inflammatory cell infiltrate in herald patches and fully developed eruptions of pityriasis rosea. Clin Exp Dermatol 35:300\u2013304. https:\/\/doi.org\/10.1111\/j.1365-2230.2009.03469.x","journal-title":"Clin Exp Dermatol"},{"key":"3763_CR32","doi-asserted-by":"publisher","first-page":"132","DOI":"10.2340\/0001555565132137","volume":"65","author":"JD Bos","year":"1985","unstructured":"Bos JD, Huisman PM, Krieg SR, Faber WR (1985) Pityriasis Rosea (Gibert): abnormal distribution pattern of antigen presenting cells in situ. Acta Derm Venereol 65:132\u2013137","journal-title":"Acta Derm Venereol"},{"key":"3763_CR33","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/1523-1747.ep12524811","volume":"87","author":"JD Bos","year":"1986","unstructured":"Bos JD, van Garderen ID, Krieg SR, Poulter LW (1986) Different in situ distribution patterns of dendritic cells having Langerhans (T6+) and interdigitating (RFD1+) cell immunophenotype in psoriasis, atopic dermatitis, and other inflammatory dermatoses. J Invest Dermatol 87:358\u2013361. https:\/\/doi.org\/10.1111\/1523-1747.ep12524811","journal-title":"J Invest Dermatol"},{"key":"3763_CR34","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/BF00424268","volume":"281","author":"JD Bos","year":"1989","unstructured":"Bos JD, Hagenaars C, Das PK, Krieg SR, Voorn WJ, Kapsenberg ML (1989) Predominance of memory T cells (CD4+, CDw29+) over naive T cells (CD4+, CD45R+) in both normal and diseased human skin. Arch Dermatol Res 281:24\u201330. https:\/\/doi.org\/10.1007\/BF00424268","journal-title":"Arch Dermatol Res"},{"key":"3763_CR35","doi-asserted-by":"publisher","unstructured":"Drago F, Ciccarese G, Broccolo F, Ghio M, Contini P, Thanasi H et al (2015) The Role of Cytokines, Chemokines, and Growth Factors in the Pathogenesis of Pityriasis Rosea. Mediators Inflamm.; 2015: 438963. https:\/\/doi.org\/10.1155\/2015\/438963","DOI":"10.1155\/2015\/438963"},{"key":"3763_CR36","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1111\/j.1468-3083.2006.01721.x","volume":"20","author":"S Gangemi","year":"2006","unstructured":"Gangemi S, Cannavo SP, Guarneri F, Merendino RA, Sturniolo GC, Minciullo PL et al (2006) The CX3C-chemokine fractalkine (CX3CL1) is detectable in serum of patients affected by active pityriasis rosea. J Eur Acad Dermatol Venereol 20:1366\u20131367. https:\/\/doi.org\/10.1111\/j.1468-3083.2006.01721.x","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3763_CR37","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1111\/j.1468-3083.2008.03067.x","volume":"23","author":"S Gangemi","year":"2009","unstructured":"Gangemi S, Minciullo PL, Guarneri F, Cristani M, Arcoraci T, Spatari G et al (2009) Increased serum levels of interleukin-22 in patients affected by pityriasis rosea. J Eur Acad Dermatol Venereol 23:858\u2013859. https:\/\/doi.org\/10.1111\/j.1468-3083.2008.03067.x","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3763_CR38","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.clindermatol.2010.03.005","volume":"28","author":"A Rebora","year":"2010","unstructured":"Rebora A, Drago F, Broccolo F (2010) Pityriasis Rosea and herpesviruses: facts and controversies. Clin Dermatol 28:497\u2013501. https:\/\/doi.org\/10.1016\/j.clindermatol.2010.03.005","journal-title":"Clin Dermatol"},{"key":"3763_CR39","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/1346-8138.12103","volume":"40","author":"E Sezer","year":"2013","unstructured":"Sezer E, Erkek E, Cetin E, Sahin S (2013) Pityriasis Rosea-like drug eruption related to rituximab treatment. J Dermatol 40:495\u2013496. https:\/\/doi.org\/10.1111\/1346-8138.12103","journal-title":"J Dermatol"},{"key":"3763_CR40","doi-asserted-by":"publisher","first-page":"S360","DOI":"10.5021\/ad.2011.23.S3.S360","volume":"23","author":"AY Cho","year":"2011","unstructured":"Cho AY, Kim DH, Im M, Lee Y, Seo YJ, Lee JH (2011) Pityriasis Rosea-Like Drug Eruption Induced by Imatinib Mesylate (Gleevec). Ann Dermatol 23:S360\u2013363. https:\/\/doi.org\/10.5021\/ad.2011.23.S3.S360","journal-title":"Ann Dermatol"},{"key":"3763_CR41","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.jaad.2013.08.056","volume":"70","author":"F Drago","year":"2014","unstructured":"Drago F, Broccolo F, Agnoletti A, Drago F, Rebora A, Parodi A (2014) Pityriasis Rosea and pityriasis rosea-like eruptions. J Am Acad Dermatol 70:196. https:\/\/doi.org\/10.1016\/j.jaad.2013.08.056","journal-title":"J Am Acad Dermatol"},{"key":"3763_CR42","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jaad.2013.09.032","volume":"70","author":"RA Schwartz","year":"2014","unstructured":"Schwartz RA, Lambert WC (2014) Pityriasis Rosea and activation of latent herpesvirus infections. J Am Acad Dermatol 70:197. https:\/\/doi.org\/10.1016\/j.jaad.2013.09.032","journal-title":"J Am Acad Dermatol"},{"key":"3763_CR43","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/rheumatology\/keq031","volume":"49","author":"T Horiuchi","year":"2010","unstructured":"Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T, Transmembrane (2010) TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology (Oxford) 49:1215\u20131228. https:\/\/doi.org\/10.1093\/rheumatology\/keq031","journal-title":"Rheumatology (Oxford)"},{"key":"3763_CR44","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/ddg.13200","volume":"15","author":"C Lindhaus","year":"2017","unstructured":"Lindhaus C, Tittelbach J, Elsner P (2017) Cutaneous side effects of TNF-alpha inhibitors. J Dtsch Dermatol Ges 15:281\u2013288. https:\/\/doi.org\/10.1111\/ddg.13200","journal-title":"J Dtsch Dermatol Ges"},{"key":"3763_CR45","first-page":"700","volume":"30","author":"C Joyau","year":"2012","unstructured":"Joyau C, Veyrac G, Dixneuf V, Jolliet P (2012) Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect? Clin Exp Rheumatol 30:700\u2013706","journal-title":"Clin Exp Rheumatol"},{"key":"3763_CR46","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1001\/archderm.1980.01640320052013","volume":"116","author":"JK Wilkin","year":"1980","unstructured":"Wilkin JK, Hammond JJ, Kirkendall WM (1980) The captopril-induced eruption. A possible mechanism: cutaneous kinin potentiation. Arch Dermatol 116:902\u2013905","journal-title":"Arch Dermatol"},{"key":"3763_CR47","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/BF00696798","volume":"32","author":"K Tischner","year":"1975","unstructured":"Tischner K, Fischer HA (1975) Uptake of tritium labelled chloroquine into organized cultures of rat spinal ganglia. An electron microscope autoradiographic study. Acta Neuropathol 32:353\u2013357. https:\/\/doi.org\/10.1007\/BF00696798","journal-title":"Acta Neuropathol"},{"key":"3763_CR48","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1001\/archderm.1982.01650150048022","volume":"118","author":"JK Wilkin","year":"1982","unstructured":"Wilkin JK, Kirkendall WM (1982) Pityriasis Rosea-like rash from captopril. Arch Dermatol 118:186\u2013187","journal-title":"Arch Dermatol"},{"key":"3763_CR49","first-page":"457","volume":"125","author":"I Ghersetich","year":"1990","unstructured":"Ghersetich I, Rindi L, Teofoli P, Tsampau D, Palleschi GM, Lotti T (1990) [Pityriasis Rosea-like skin eruptions caused by captopril]. G Ital Dermatol Venereol 125:457\u2013459","journal-title":"G Ital Dermatol Venereol"},{"key":"3763_CR50","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/j.1468-3083.2004.01055.x","volume":"18","author":"L Atzori","year":"2004","unstructured":"Atzori L, Ferreli C, Pinna AL, Aste N (2004) Pityriasis Rosea-like\u2019 adverse reaction to lisinopril. J Eur Acad Dermatol Venereol 18:743\u2013745. https:\/\/doi.org\/10.1111\/j.1468-3083.2004.01055.x","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3763_CR51","first-page":"704","volume":"40","author":"H Yahya","year":"2023","unstructured":"Yahya H (2023) Pityriasis Rosea in Kaduna, North-West Nigeria: a 20-Year experience. West Afr J Med 40:704\u2013710","journal-title":"West Afr J Med"},{"key":"3763_CR52","doi-asserted-by":"publisher","first-page":"29","DOI":"10.4314\/nqjhm.v20i1.57989","volume":"20","author":"O Ayanlowo","year":"2010","unstructured":"Ayanlowo O, Akinkugbe A, Olumide Y (2010) The pityriasis rosea calendar: a 7 year review of seasonal variation, age and sex distribution. Nig Q J Hosp Med 20:29\u201331. https:\/\/doi.org\/10.4314\/nqjhm.v20i1.57989","journal-title":"Nig Q J Hosp Med"},{"key":"3763_CR53","first-page":"60","volume":"30","author":"WK Cheong","year":"1989","unstructured":"Cheong WK, Wong KS (1989) An epidemiological study of pityriasis rosea in Middle Road Hospital. Singap Med J 30:60\u201362","journal-title":"Singap Med J"},{"key":"3763_CR54","first-page":"829","volume":"28","author":"YK Tay","year":"1999","unstructured":"Tay YK, Goh CL (1999) One-year review of pityriasis rosea at the National Skin Centre, Singapore. Ann Acad Med Singap 28:829\u2013831","journal-title":"Ann Acad Med Singap"},{"key":"3763_CR55","unstructured":"Field MJ, Boat TF (eds) (2012) Safe and Effective Medicines for Children: Pediatric Studies Conducted Under the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act. Washington (DC)"},{"key":"3763_CR56","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nrrheum.2010.142","volume":"6","author":"PJ Hashkes","year":"2010","unstructured":"Hashkes PJ, Uziel Y, Laxer RM (2010) The safety profile of biologic therapies for juvenile idiopathic arthritis. Nat Rev Rheumatol 6:561\u2013571. https:\/\/doi.org\/10.1038\/nrrheum.2010.142","journal-title":"Nat Rev Rheumatol"},{"key":"3763_CR57","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1007\/s43441-023-00542-0","volume":"57","author":"M Phan","year":"2023","unstructured":"Phan M, Cheng C, Dang V, Wu E, Munoz MA (2023) Characterization of Pediatric reports in the US Food and Drug Administration adverse event reporting system from 2010\u20132020: a cross-sectional study. Ther Innov Regul Sci 57:1062\u20131073. https:\/\/doi.org\/10.1007\/s43441-023-00542-0","journal-title":"Ther Innov Regul Sci"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03763-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-03763-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03763-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T12:02:20Z","timestamp":1736769740000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-03763-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,13]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3763"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-03763-x","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,13]]},"assertion":[{"value":"10 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Since the FAERS database is openly accessible to the public and patient data is anonymized and de-identified, ethical clearance and informed consent are not required for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"231"}}